Are Bleeding Events Valid as a Surrogate Endpoint for Mortality in Cardiovascular Clinical Trials?

Affiliations

Editorial

Seng Chan You. JACC Adv. 2023.

. 2023 May 26;2(3):100335.

doi: 10.1016/j.jacadv.2023.100335. eCollection 2023 May.

¹ Department of Biomedical Systems Informatics, College of Medicine, Yonsei University, Seoul, Korea.

No abstract available

Keywords: bleeding; patient-centered care; surrogate.

Conflict of interest statement

Dr You is a chief technology officer of PHI Digital Healthcare.

1. Djulbegovic B., Guyatt G.H. Progress in evidence-based medicine: a quarter century on. Lancet. 2017;390:415–423. - PubMed
1. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet. 1986;2:57–66. - PubMed
1. SOLVD Investigators. Yusuf S., Pitt B., Davis C.E., Hood W.B., Cohn J.N. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302. - PubMed
1. Digitalis Investigation Group The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–533. - PubMed
1. Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Gruppo Italiano per lo Studio della Streptochi-nasi nell’Infarto Miocardico (GISSI) Lancet. 1987;2:871–874. - PubMed